Clinical Trial

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

Study acronym: ENRICH-AF
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2026 (before its estimated May 13, 2026 completion). Its status may not reflect the trial's current state.
Summary
To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) or systemic embolism in high-risk atrial fibrillation (CHA2DS2-VASc ≥2) patients with previous intracranial hemorrhage.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-05-13; most recent amendment 2026-02-23.
Status change: Recruiting → Active, Not Recruiting 2025-01-14
Status change: Not Yet Recruiting → Recruiting 2019-10-25
Trial Details
NCT Number NCT03950076
Lead Sponsor Population Health Research Institute
Conditions Intracranial Hemorrhages, Atrial Fibrillation
Enrollment 948 participants
Start Date 2019-09-20
Primary Completion 2026-05-13 (estimated)
Study Completion 2026-05-13 (estimated)
Updated on ClinicalTrials.gov 2026-02-25